Barclays PLC increased its holdings in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 147.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 89,650 shares of the biotechnology company's stock after acquiring an additional 53,354 shares during the period. Barclays PLC owned about 0.20% of Capricor Therapeutics worth $1,238,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Summit Investment Advisors Inc. boosted its holdings in Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 1,345 shares in the last quarter. Kennedy Capital Management LLC bought a new position in shares of Capricor Therapeutics during the 4th quarter worth approximately $1,991,000. Legal & General Group Plc boosted its stake in Capricor Therapeutics by 1,029.7% in the 4th quarter. Legal & General Group Plc now owns 30,783 shares of the biotechnology company's stock valued at $425,000 after buying an additional 28,058 shares in the last quarter. Invesco Ltd. grew its position in Capricor Therapeutics by 20.5% in the fourth quarter. Invesco Ltd. now owns 14,678 shares of the biotechnology company's stock valued at $203,000 after acquiring an additional 2,500 shares during the period. Finally, Russell Investments Group Ltd. raised its stake in Capricor Therapeutics by 172.8% during the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock worth $64,000 after acquiring an additional 2,947 shares in the last quarter. Institutional investors own 21.68% of the company's stock.
Capricor Therapeutics Price Performance
Shares of Capricor Therapeutics stock opened at $11.86 on Monday. The firm has a 50 day simple moving average of $11.84 and a 200 day simple moving average of $14.58. Capricor Therapeutics Inc has a fifty-two week low of $3.52 and a fifty-two week high of $23.40. The firm has a market cap of $541.73 million, a P/E ratio of -11.19 and a beta of 0.85.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The company had revenue of $11.13 million during the quarter, compared to analysts' expectations of $9.87 million. On average, sell-side analysts expect that Capricor Therapeutics Inc will post -1.21 EPS for the current year.
Wall Street Analysts Forecast Growth
CAPR has been the topic of several analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $77.00 target price on shares of Capricor Therapeutics in a report on Monday, March 17th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $30.00 price objective on shares of Capricor Therapeutics in a research note on Thursday, March 20th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $34.50.
Read Our Latest Research Report on CAPR
Capricor Therapeutics Profile
(
Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Stories
Want to see what other hedge funds are holding CAPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
